Novo Nordisk says its high-dose semaglutide trial shows 20.7% weight loss
Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...
Novo Nordisk Unusual Options Activity
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Novo Nordisk (0QIU) Receives a Buy from J.P. Morgan
In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price ...
devdiscourse7h
Medicare Price Negotiations Target Diabetes and Weight-loss Drugs
Novo Nordisk's Ozempic and Wegovy are among 15 drugs targeted for Medicare price negotiations in 2027. The U.S. aims to cut ...
FiercePharma7h
Novo's semaglutide among 2nd batch of drugs selected for IRA price negotiations
The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...
LVMH overtakes Novo Nordisk as Europe’s most valuable company
Luxury bellwether regains crown as drugmaker slips on concerns it will have to cut weight loss medication prices in US ...
BioSpace4h
Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss in Phase III Trial
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
Finally An Attractive Entry Point Into Novo Nordisk
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...